Overview
The Hugo RAS (Robotic-Assisted Surgery) System is Medtronic's entry into the robotic minimally invasive surgery market — the most strategic product in the company's $35B surgical portfolio. Hugo's modular architecture distinguishes it from the da Vinci's fixed tower design, offering separate arm carts that can be configured independently for each procedure, potentially reducing OR footprint and setup complexity.
Hugo features wristed endoscopic instruments, 3D HD visualization through an open console (no immersive headset), and integration with Medtronic's Touch Surgery Enterprise cloud platform — enabling procedure performance analytics, skill assessment, and telestration for surgical education. This data layer represents Medtronic's vision for robot-powered surgical intelligence beyond the OR.
Hugo received CE Mark in 2021 and is commercially active across Europe, Middle East, Asia, and Latin America. The US FDA submission is pending, with clearance for urology and gynecology procedures anticipated. The US launch would pit Hugo directly against Intuitive Surgical's da Vinci in the world's largest robotic surgery market.
Key Technology
🧩
Modular Arm Architecture
Independent arm carts can be positioned and configured separately per procedure — unlike fixed-tower competitors. Enables more flexible OR configuration across room sizes.
🎥
3D HD Open Console
Surgeon operates from an ergonomic open-architecture console with 3D HD vision system. Unlike the da Vinci's closed console, Hugo's open design maintains OR situational awareness.
☁️
Touch Surgery Enterprise
Cloud platform captures OR video, overlays step recognition AI, and generates performance analytics by surgeon, procedure type, and institution — enabling system-wide quality benchmarking.
🔧
Wristed Instruments
7-degree-of-freedom wristed instruments deliver natural wrist motion with tremor filtration and motion scaling, matching da Vinci's instrument articulation capability.
Pivotal Trial: EXPAND
FDA Pivotal
EXPAND MIS Trial (Urology + Gynecology)
Multi-center IDE pivotal trial evaluating Hugo for robotic prostatectomy, hysterectomy, and sacrocolpopexy. Primary endpoint: non-inferiority to standard laparoscopic MIS for conversion rate and major adverse events. Data expected to support US FDA submission.
Real-World CE Mark Data
European Commercial Experience (1,000+ Cases)
Post-market data from European launch centers shows Hugo clinical outcomes consistent with established robotic benchmarks for prostatectomy, nephrectomy, and colorectal resection. No unanticipated safety signals reported.
AI / Analytics
Touch Surgery Procedure Intelligence
Hugo's AI step-recognition system has been validated across 15+ robotic procedure types, generating automated surgical process metrics that correlate with clinical outcomes in published studies.
Regulatory Timeline
2019
Hugo RAS formally announced; Medtronic acquires Touch Surgery to build data layer
2021
CE Mark approved; commercial launch begins in Europe, Middle East, Asia
2022
EXPAND IDE pivotal trial begins enrollment at US sites
2023
FDA submission filed for urology + gynecology; Panel review scheduled
2025
FDA review ongoing; US launch clearance highly anticipated; 100+ international sites active